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Binding of dimeric and polymeric IgA to rat renal mesangial cells
enhances the release of interleukin 6
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Binding of dimeric and polymeric IgA to rat renal mesangial cells
enhances the release of interleukin 6. The mesangium plays a crucial role
in processes of inflammation in the kidney. Since deposits of IgA in the
mesangium in patients with IgA nephropathy suggest a role for IgA in the
inflammatory process, we investigated whether IgA is able to bind to
cultured rat mesangial cells (MC) in vitro and induce activation of MC. As
a source of IgA, monomeric (mIgA), dimeric (dIgA) and polymeric
IgA-a-DNP (pIgA) rat monoclonal antibodies were used. FACS analysis
indicated binding of dIgA and pIgA to MC while only a small percentage
of the cells exhibited binding of mIgA. Additional experiments employing
radiolabeled IgA revealed a time- and dose-dependent binding of 1251
dIgA and '251-pIgA with 6• 106 binding sites for dIgA with an affinity of
5.5 106 M1 and 7.2 j6 binding sites/cell for pIgA with an affinity of
1.2 106 M1. As compared to 'I-dIgA and 1251-pIgA, little binding
of 1251-mIgA to MC occurred; the binding of dIgA and pIgA was not
influenced by excess cold BSA, IgG or asialofetuin. Since some studies
have suggested that fibronectin might interact with IgA, the binding of IgA
to MC in the presence or absence of fibronectin or the RGD fragment was
also analyzed. However no influence of fibronectin or the RGD fragment
on binding of dIgA and pIgA to MC was observed. As a measure for
activation of MC by IgA, the production of IL-6 by MC was analyzed.
Dimeric IgA and pIgA both induced a dose-dependent increase of IL-6
production by MC. These studies suggest that especially dIgA and pIgA
are potent activators of MC, while mIgA is relatively ineffective in this
respect.
Primasy IgA nephropathy (IgAN) is a common form of glomer-
ulonephritis characterized by granular deposits of IgA in the
mesangial area of the glomerulus. The glomerular IgA is mainly of
the IgAl subclass, and at least in part of dimeric and polymeric
origin, and presumably derived from the circulation [1, 2]. Ele-
vated levels of IgA have been found in serum of patients with
IgAN [3] and a hyperresponse for IgAl has been shown to occur
upon vaccination [4]. Other immunoglobulins may also be found
in the affected glomeruli of IgAN patients: IgG is reported in 45%
to 83% of the biopsies and 1gM in 9% to 66% [5]. Complement
component C3 is reported in 4% to 100% of the biopsies [5] and
is frequently associated with deposits of properdin, factor B and
factor H [6, 7]. The disease leads slowly to renal failure in a
substantial percentage of the patients.
The question at present is whether these IgA complexes are
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generated locally by interactions with antigens trapped in the
mesangial area, because of size or via specific binding to potential
IgA receptors. While it has been shown [8] that sera of patients
with IgAN have IgG antibodies against defined mesangial cell
antigens, no detectable binding of IgA or 1gM antibodies to
mesangial cells has been reported yet. Van den Wall Bake et al [9]
found increased binding of IgA from sera of patients with IgAN to
collagens types I, V and whole kidney extract. Binding of IgA to
collagen type V was not influenced by fibronectin and may
therefore reflect antibody activity of these IgA molecules.
On the other hand, receptors for IgA have been documented on
human monocytes and macrophages [10—15], neutrophils [15, 16],
eosinophils [17] and on T- [18] and B-lymphocytes [19, 20].
Binding of IgA to specific IgA receptors promotes degranulation
of eosinophils [17], mediates phagocytosis of IgA coated particles
by monocytes [10, 11, 21] and neutrophils, and may result in
activation of, for example, PMNs to generation of H202 [16, 22]
or stimulation of chemokinesis [23]. Binding of IgA to rat
peritoneal macrophages and subsequent activation has also been
described [24, 25]. The receptor for IgA (Fca-R) from monocytes/
macrophages and granulocytes has been isolated, cloned [261 and
characterized as a heavily glycosylated transmembrane molecule
of 55 to 75 kDa that is able to bind both IgAl and IgA2 [14, 16]
in monomeric and polymeric form. Fccs-R expression is up-
regulated by PMA and polymeric IgA [14].
Because mesangial IgA deposits in patients with IgAN have
been described to be associated with increased levels of interleu-
kin 6 (IL-6) in the urine [27, 28] we have investigated whether
binding of IgA to mesangial cells (MC) is receptor mediated and
whether binding of IgA results in activation of the cells and
subsequent release of IL-6.
Methods
Materials
RPMI-1640 (Seromed, Biochrom K.G., Berlin, Germany),
13-mercaptoethanol (Merck, Amsterdam, The Netherlands), fetal
calf serum (FCS) (Hyclone, Utah, USA), asialofetuin (ASFe),
BSA, gelatin, cycloheximide, fibronectin-like multiple RGD (Arg-
Gly-Asp) containing polypeptide (Sigma Chemical Company, St.
Louis, Missouri, USA), Sephacryl S300 (Pharmacia, Woerden,
The Netherlands), Dowex 1X8, dispase (Brunschwig Chemicals,
Amsterdam, The Netherlands), Biogel AS (Biorad Laboratories,
Richmond, Virginia, USA), lodobeads (Pierce Chemical Co,
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Rockford, Illinois, USA), Na'251 (The Radiochemical Center,
Amersham, UK), rabbit anti-fibronectin (Telios Pharmaceuticals,
San Diego, California, USA) were purchased as indicated. LDH
measurements were performed according to the procedure of
Dimension (Du Pont, Wilmington, Delaware, USA).
Mesangial cell culture
Glomeruli were isolated from renal cortices of Sprague-Dawley
rats by mechanical dissociation and sequential sieving as described
previously [28, 29]. The conditions used for the growth of rat MC
were reported earlier [28]. They were characterized as MC using:
(a) morphology, (b) uniform fluorescence with FITC-phalloidin
for actin, (c) positive staining for mouse anti-rat Thyl for more
than 98% 4% of all nucleated cells, and (d) absence of
immunofluorescence using anti-factor VIII antibodies or antibod-
ies for cytokeratin.
For further experiments, MC from passage 2 to 10 in T75
(Greiner) bottles were washed, trypsinized and subcultured an-
other three to four days in 12-well microtiter plates (Costar)
(8 io cells/well) or in 48-well microtiter plates (Costar) (2 i04
cells/well) in RPMI-1640 containing 5% FCS and 5 i0- M
p-mercaptoethanol.
Isolation and radioiodination of rat monoclonal IgA
Ascites from two rat hybridoma cell lines producing either
monomeric IgA (LO-DNP-58) or mainly dimeric and polymeric
IgA (LO-DNP-45) with specificity for dinitrophenol (DNP) were
obtained from Louvain C rats. Rat IgA monoclonal antibodies
from clone LO-DNP-45 were isolated as described with slight
modifications [30, 31]. Briefly, IgA-containing ascites was precip-
itated with 50% (NH4)2S04 followed by absorption to and elution
from DNP-lysine Sepharose affinity column using 0.1 M DNP.
After removal of free DNP by chromatography on Dowex 1X8,
the IgA antibodies were further fractionated according to size by
gel fractionation on Sephacryl S300 to yield dimeric IgA (10.3 S)
and polymeric IgA (12 to 15 S). Monomeric IgA anti-DNP (7 S)
from clone LO-DNP-58 was isolated from ascites following the
same procedure. The purified IgA preparations contained no
detectable amounts of IgG and 1gM as detected by ELISA. There
are no detectable differences in biophysical characteristics of IgA
isolated from the two cell lines, as has been described extensively
by Rits et al [30]. The IgA preparations were aliquoted and stored
at —80°C.
For binding studies, purified monomeric IgA (mIgA), dimeric
IgA (dIgA) and polymeric IgA (pIgA) were radiolabeled with 125J
in the presence of lodobeads for 20 minutes at room temperature
to specific activities of approximately 0.3 j.Ci/tg protein. Protein
bound iodine was separated from free iodine by extensive dialysis
against PBS.
Isolation of fibronectin
Native fibronectin (FBN) was isolated from citrated plasma by
affinity chromatography on a Biogel AS-gelatin column [32].
Fractions positive for fibronectin as measured by ELISA were
pooled, concentrated and stored at —80°C. The purified fibronec-
tin preparation contained no detectable amounts of IgG, IgA or
1gM as measured by ELISA; there were no further contamina-
tions as judged by 5% SDS-PAGE.
FACS analysis
MC were detached with dispase, washed two times and resus-
pended in PBS/1% BSA (1 .i0 cells/ml). MC (1 . 106 cells) were
then incubated with mIgA, dIgA and pIgA at concentrations of 5,
10 and 20 jLg/ml for one hour at 4°C. Thereafter the cells were
washed with PBS/i % BSA and subsequently incubated with FITC
conjugated rabbit anti-rat IgA antibodies for 30 minutes at 4°C.
The polyclonal rabbit anti-rat IgA was prepared in our laboratory
and conjugated with FITC (8 mg/ml, F/P ratio 2.5, working
dilution 1/100). After washing with PBS/1% BSA, MC were fixed
with 1% paraformaldehyde and fluorescence assessed by FACS
(Becton Dickinson).
Binding studies
Binding of IgA to MC was studied as follows: MC seeded in
48-well microtiter plates were cultured for another three to four
days in RPMI-1640 containing 5% FCS and 5 iO M
-mercap-
toethanol. Before each experiment, all wells were washed three
times with PBS/0.5% BSA and three wells were trypsinized so that
the average number of cells present at the beginning of the assay
could be counted by Coulter Counter (Coulter Electronics, Mij-
drecht, The Netherlands). Known amounts of either 11-mIgA,
'251-dIgA or '251-pIgA in 300 d RPMI/0.5% BSA were added to
MC either for a fixed time period or for various time intervals at
4°C in triplicate. After the desired time period, all wells were
washed three times with PBS/0.5% BSA and 300 jil of 1 MNaOH
was added to each well to detach and solubilize the cells. The
amount of radioactivity was determined subsequently. The
amount of ligand bound was calculated from the total input and
the specific radioactivity per g ligand on a iO cell number. Wells
without cells were used as controls to determine the amount of
non-specific binding. All data were corrected for non-specific
binding. Background binding was 8.9% 4.6% of total binding as
calculated from all experiments performed.
To determine the specificity of binding of 1I-dIgA and
'251-pIgA to MC, experiments were performed with 125I-dIgA and
1251-pIgA (1 pg/well) in the presence of excess unlabeled dIgA or
pIgA (3.12 to 100 p.g/well). As control proteins BSA, IgG or
asialofetuin (100 .ig/well) were included. All experiments were
performed for 16 hours at 4°C; the amount of cell-bound radio-
activity was assessed as described above.
Production of IL-6 by MC
MC in 48 well plates were washed three times with sterile PBS
and three wells were trypsinized to count the number of cells
present at the beginning of the assay. MC were incubated with
various concentrations mIgA, dIgA and pIgA in RPMI-1640
containing 5% FCS, /3-mercaptoethanol in the presence or ab-
sence of 1 jLg/ml polymyxin-B. After 24 hours of culture, super-
natants were harvested and tested for IL-6 activity using the IL-6
dependent murine hybridoma cell line (B9), provided by Dr. L.A.
Aarden (CLB, Amsterdam, The Netherlands) [28, 33]. Cell
proliferation was measured using the colorimetric Cell Titer 96
assay (Promega, Leiden, The Netherlands). In our hands, no
difference was found in the detection of IL-6 concentrations using
either the 3H-thymidine incorporation or the Cell Titer 96 assay.
100
Fig. 1. MC were incubated with PBS (A), mIgA (B), dIgA (C) and pIgA (D) in a concentration of 20 pg/welL Cells were stained with rabbit
anti-rat-IgA-FITC and assessed for fluorescence by FACS. Incubation of MC with dIgA and pIgA resulted in a clear positive fluorescence, whereas
mIgA only exhibited a binding of 8.4% as compared to the PBS control (4%).
Statistical analysis
Statistical analysis were performed using Student's t-test for
unpaired samples and a P value of 0.05 was used to determine
significance.
Results
FACS analysis of MC incubated with PBS (Fig. 1A), mIgA (Fig.
1B), dIgA (Fig. 1C) and pIgA (Fig. 1D), each at a concentration
of 20 .tgfml, revealed binding for all three preparations with 3.6%
of the cells positive with a mean fluorescence of 4 for PBS, 8.4%
of the cells pos/itive with a mean fluorescence of 6 for mIgA,
65.8% of the cells positive with a mean fluorescence of 25 for
dIgA and 72.2% of the cells positive with a mean and fluorescence
of 31 for pIgA. At the concentrations used, the binding of mIgA
to MC was not significantly different from the PBS control (mean
from 4 experiments was 4.8% 2%). When different concentra-
tions were used, there was a dose-dependent effect of binding of
all three IgA preparations to MC; however, pIgA bound better to
MC than dIgA and mIgA at all concentrations tested.
To determine the kinetics of binding of '251-mIgA, 1I-dIgA
and 1251-pIgA, these preparations (1 pg/well) were incubated with
MC for various time periods between 2 and 24 hours at 4°C,
washed, and cell associated radioactivity determined. There was a
time-dependent binding of all three preparations which was
saturated between 8 and 16 hours (data not shown). For all
further experiments a time point of 16 hours was chosen.
The '251-radiolabeled antibodies were incubated with MC in
concentrations ranging from 1.25 to 10 .g/well. After 16 hours of
incubation at 4°C, MC were washed and the amount of cell-bound
radioactivity was assessed. There was a dose-dependent binding of
pIgA; dIgA also exhibited binding to MC but was 2.5- to 3-fold
less than pIgA in the concentrations tested. Monomeric IgA only
bound significantly to MC above an input of 10 jgIwell (Fig. 2).
To investigate the specificity of binding of 1251-dIgA and
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Fig. 2. Incubation of MC with increasing concentrations 1251-mIgA, 125j
dIgA and '251-pIgA for 16 hours at 4°C resulted in a dose-dependent specific
binding of all three preparations to MC. However, at all concentrations
tested pIgA bound better to MC than dIgA which again bound better to
MC than mIgA (* P < 0.05, ** P <0.01, °° P< 0.001). Symbols are: (El)
1.25 sg/well; () 2.5 gIwell; (VA) 5 .tglwell; (0)10 gIwell.
1251-pIgA to MC, cells were incubated with 1251-dIgA or 1251-pIgA
alone (1 j.Lg/well) or in the presence of excess unlabeled dIgA
(3.12 to 100 g/well) and pigA (3.12 to 50 g/weIl), respectively.
BSA, IgG and asialofetuin (100 p.g/well) were used as control
proteins. After 16 hours of incubation at 4°C, the amount of
cell-bound radioactivity was assessed. In the absence of unlabeled
IgA, 25.5 4.4 ng '251-dIgA was bound/105 cells and 41.9 8.9
ng of 1251-pIgA bound/105 cells. The presence of excess unlabeled
dIgA and pIgA resulted in a dose-dependent inhibition of binding
with 70.2% 10.6% inhibition of binding of 1251-dIgA (Fig. 3A)
and 78.8% 0.7% inhibition of binding of '251-pIgA (Fig. 3B) in
the highest concentrations tested; the presence of BSA, IgG and
asialofetuin had no significant effect (Fig. 3). The binding of
1251-pIgA could also be inhibited with increasing concentrations
dIgA and vice versa, whereas mIgA was only able to inhibit the
binding of 1251-dIgA and of 1251-pIgA for 38% 6% at a 100-fold
excess.
To quantify the binding of the IgA preparations to MC, the data
from experiment 3 were used and subsequently analyzed accord-
ing to Scatchard [341. These results indicate an average number of
6 106 binding sites/cell for dIgA with an average affinity of
5.5• 106 M1 (Fig. 4), there were 7.2 106 binding sites/cell for
pIgA with an average affinity of 1.2 106 M1.
It has been suggested that IgA may interact with fibronectin and
subsequently with the collagen matrix produced by MC. To test
the possibility that binding of IgA to MC was influenced by
fibronectin, MC were incubated with 1251-dIgA (1.5 gig/well) alone
or in the presence of increasing concentrations of dIgA, native
fibronectin or the multiple RGD-containing fragment of fibronec-
tin. After 16 hours of incubation, the amount of cell-bound
radioactivity was assessed. We observed a binding of 46.4 5.5
ng/105 cells for 1251-dIgA alone and this binding was not influ-
enced by increasing concentrations unlabeled fibronectin or the
multiple RGD-containing fragment of fibronectin (Fig. 5), while
dIgA was able to inhibit the binding of 1251-dIgA dose-depen-
dently. Also incubation of the cells with a rabbit anti-fibronectin
antibody in the presence of '251-dIgA or 1251-pIgA did not
influence the binding of '251-dIgA or '251-pIgA to MC.
o 3.12 6.25 12.5 25 50 BSA/lgG/ASFe
pigA concentration, pg/well
Fig. 3. Specificity of binding of '25I-dIgA (A) and '251-pIgA (B) was shown
by incubation of '251-dIgA and '251-pIgA alone or in the presence of
increasing concentrations unlabeled dIgA orplgA, respectively, and BSA, IgG
and asialofetuin as control proteins. Incubation of MC in the presence of
excess dIgA or pIgA resulted in a dose-dependent inhibition of specific
binding of 1251-dIgA and '251-pIgA to MC. All control proteins were not
able to inhibit the binding of 1251-dIgA or '251-pIgA to MC (° P < 0.05;
**P < 0.01, P < 0.001).
Since the results described above suggested the presence of
specific binding sites for IgA on MC, we investigated whether
binding of IgA to MC also results in activation of MC. Therefore
MC were cultured for 24 hours at 37°C in medium alone or
medium containing 10, 50 and 250 .tg/ml mIgA, dIgA or pIgA in
the presence or absence of polymyxin-B and assessed for IL-6 in
the B9 assay. Both dIgA and pIgA enhanced the production of
IL-6 in a dose-dependent fashion while mIgA was only able to
enhance the release of IL-6 significantly at an input of 250 ig/ml
(Fig. 6). The results were comparable irrespective of the presence
or absence of polymyxin-B.
Evidence for de novo synthesis of IL-6 was obtained by blocking
the production of IL-6 with cycloheximide. MC were incubated in
medium alone or medium containing IgA (100 Lg/ml) with or
without cycloheximide (1 j.Lg/ml). After 48 hours of incubation,
supernatants were removed for IL-6 analysis by the B9 assay. For
this purpose, MC supernatants were diluted 1/20 to 1/640 to assess
the amount of IL-6. Control medium with or without 1 .tg/m1
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Fig. 4. Dose-dependent specific binding of dIgA
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to MC. Inset. Scatchard analysis of binding of
dIgA to MC.
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Fig. 5. Specificity of binding of IgA to MC was shown by incubation of MC
with '251-dJgA in the presence of increasing concentrations flbronectin or the
multiple RGD-containing fragment. Symbols are: (LI—11J) RGD frag-
ment; (L\----A) FBN; (0—0) digA. In all concentrations tested, neither
fibronectin nor the RGD-fragment were able to inhibit the specific binding
of '251-dIgA to MC, whereas dIgA inhibited the specific binding of
'251-dIgA in a dose-dependent fashion (° P < 0.05, ** P < 0.002).
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Fig. 6. MC were incubated with increasing concentrations of migA (0),
digA (A) and pigA ([1) for 24 hours at 37°C. Supernatants were harvested
and assessed for IL-6 by the B9 assay. Dimeric IgA and pIgA were able to
enhance the release of IL-6 in a dose-dependent fashion, whereas mIgA
only enhanced a significant release of IL-6 at the highest concentration
tested (* P < 0.05).
medium without cycloheximide. At a concentration of 1 kg/ml
cycloheximide used, no cytotoxicity of the cells was seen as
assessed by LDH measurements.
Discussion
Binding of IgG immune complexes or soluble aggregates of IgG
to rat MC has been described [28, 35]. In the present study we
cycloheximide was also used in dilutions from 1/20 to 1/640. The
wells were trypsinized and harvested for the assessment of the
number and viability of the cells. The results were calculated and
expressed on a i0 cell basis. These experiments revealed that
cycloheximide inhibited the IgA-induced IL-6 release with 90%
8% (Fig. 7). No effect of cycloheximide in the B9 assay was
observed in medium containing cycloheximide as compared to
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human IgAl due to the presence of galactose residues in the hinge
region of IgAl [41]. Third, binding of IgA to specific Fca
receptors has been described on human monocytes [10—15],
neutrophils [15, 16], eosinophils [17] and on T- [18] and B-cells
[19, 20]. Binding of IgA to this receptor can result in activation of
the cells leading to phagocytosis [16, 21, 25].
Characterization of the Fccw receptor from the human cell line
U937 revealed a 55 to 75 kDa molecule which could be up-
regulated with PMA and pigA [14, 16]. Fargeas et al [42] isolated
a 56 and 70 kDa molecule under reducing and non-reducing
conditions from rat peritoneal macrophages. Whether there are
two types of receptors present on rat peritoneal macrophages or if
this molecule represents two subunits of the receptor is not clear
yet. Probably there are some differences in the receptors isolated
from human and rat cells although the receptors are both able to
bind rat and human IgA.
In the kidney, other binding mechanisms could also play a role
in binding of IgA. MC produce a mesangial matrix which is known
to contain fibronectin [43] and in patients with IgAN circulating
complexes of IgA with fibronectin have been reported [44]. To
exclude the possibility that binding of IgA occurs via fibronectin,
we showed that binding could not be inhibited in the presence of
increasing concentrations fibronectin or the multiple RGD con-
taining binding fragment suggesting the presence of a specific
binding site for IgA. Incubation of the cells with rabbit anti-
fibronectin antibodies did not influence the binding of 1251-dIgA
and '251-pIgA to MC.
The putative Fca receptor on MC is also functionally active.
The binding of mIgA, dIgA and pIgA is dose-dependent and
dependent on the size of the IgA preparation. Interestingly,
incubation of MC with mIgA, dIgA and pIgA also resulted in a
size-dependent production of IL-6 by MC. This effect was also
dose-dependent. The production of IL-6 by MC after stimulation
with IgA could be inhibited by cycloheximide suggesting de novo
synthesis of the IL-6 molecule. The inhibition of IL-6 release was
not caused by cytotoxicity of the cycloheximide since LDH
measurements showed no significant differences between treated
and non-treated cells.
The presence of a Fccw receptor on MC could play a role in
deposition of IgA in the mesangial area of IgAN patients. It has
been described that patients with IgAN have increased levels of
IL-6 in their urine which could be a result of an enhanced IL-6
release by MC after interaction with IgA molecules. In vitro, it has
been shown that IL-6 is an autocrine growth factor for MC which
could stimulate the cells to proliferate. Also in vivo, a positive
correlation between the production of IL-6 and mesangioprolif-
erative glomerulonephritis was shown in a mouse model [45];
mice transfected with the human IL-6 gene not only had high
levels of plasma IL-6, but also showed a profound mesangial
proliferation. This suggests that an increased production of IL-6
in the mesangium may be responsible for the pathological prolif-
eration of MC in GN. Probably several other mechanisms con-
tribute to the formation of deposits, such as interactions with
matrix components [9] and alterations in the IgA molecules
themselves, for example, the carbohydrate composition which
could occur in patients with IgAN. Whether patients with IgAN
express more mRNA for IgA receptors than healthy controls will
be studied in the future with in situ hybridization techniques. This
may give insight into the question of whether Fca receptors play
a role in the pathology of IgAN.
Medium IgA
Fig. 7. MC were incubated with medium or pIgA alone (LI) or in the
presence of I pg/mi cycloheximide (). After 48 hours of incubation at
37°C the supernatants were harvested and assessed for IL-6. The IgA-
induced IL-6 release was inhibited 90% 8% by cycloheximide suggesting
a de novo synthesis of IL-6 by IgA (* P < 0.001). No cytotoxicity occurred
as assessed by LDH-measurements.
demonstrate that dIgA and pigA preferentially bind to MC and
result in activation of MC as assessed by release of IL-6. We
showed that the binding of mIgA, dIgA and pIgA occurred in a
time- and dose-dependent fashion as assessed by FACS analysis
or binding of '251-radiolabeled IgA preparations. When binding of
the 25I-IgA preparations to MC was expressed on a relative basis,
ratios of 1:2.5:6.8 were found for mIgA, dIgA and pIgA, respec-
tively, at an input of 10 xg/weIl.
Specificity of binding of IgA was shown using 1251-dIgA and
1251-pIgA in the presence of excess unlabeled dIgA or pIgA,
respectively. Binding of 1251-dIgA and '251-pIgA was only inhib-
ited by dIgA and pIgA, respectively, and not by BSA or IgG,
suggesting that specific receptors for IgA are present on rat MC.
Indeed, similar results were published recently [36] using human
myeloma monomeric IgA. A specific receptor for IgA of 55 to 66
kDa was immunoprecipitated from rat MC and specific mRNA
encoding for FexsR was demonstrated. Also asialofetuin was not
able to inhibit binding of IgA to MC, suggesting that binding of
IgA does not occur via the sugar residues of the IgA molecule. To
quantify the number of receptors per cell, Scatchard analysis was
performed. We observed 6 106 binding sites per cell for dIgA
with an affinity of 5.5 106 M1 and 7.2 106 binding sites per cell
for pIgA with an affinity of 1.2 106 M1. Recently Gómez-
Guerrero, Gonzalez and Egido [36] described the presence of
1 io binding sites per rat MC with an average affinity of
7.8• 108 M1. In this system, however, human monomeric IgA was
used to determine the number of binding sites per cell which
could have a different affinity for the cell as compared with rat
IgA.
At present, three different receptors capable of binding human
IgA have been described. First, the secretory component receptor,
expressed on rodent hepatocytes [37] and a variety of epithelial
cells [38], is a membrane protein which mediates transcellular
transport of J-chain-containing polymeric IgA and polymeric 1gM
into external secretions. Second, the asialoglycoprotein receptor,
which has been demonstrated on rabbit, rat and human hepato-
cytes [39], rat peritoneal macrophages and Kupifer cells [24, 40].
This receptor has a specificity for galactose and is able to bind
518 van den Dobbelsteen et a!: IgA enhances the release of IL-6 by MC
Acknowledgment
This study was supported by the Dutch Kidney Foundation, grant
number 89.0924.
Reprint requests to Marieke E.A. van den Dobbelsteen, Department of
Nephrology, University Hospital Leiden, Building 1, C3P, P.O. Box 9600,
2300 RC Leiden, The Netherlands.
References
1. CONLEY ME, COOPER MD, MICHAEL AF: Selective depositions of
immunoglobulin Al in immunoglobulin A nephropathy, anaphylac-
toid purpura nephritis and systemic lupus erythematosus. J C/in Invest
66:1432—1436, 1980
2. VALENTIJN RM, RADL J, HAAIJMAN JJ, VERMEER BJ, WEaNING JJ,
KAUFMAN RH, DAHA MR, VAN Es LA: Circulating and mesangial
secretory component-binding IgAl in primary IgA nephropathy.
Kidney mt 26:760—766, 1984
3. VAN DEN WALL BAKE AWL, DAHA MR, VAN DER Arx A, HIEMSTRA
PS, RADL J, VAN Es LA: Serum levels and in vitro production of IgA
subclasses in patients with primary IgA nephropathy. C/in Exp Immu-
no! 74:115—120, 1988
4. VAN DEN WALL BAKE AWL, BaYER WEP, EVERS-SCHOUTEN JH,
DANA MR, VAN Es LA: The humoral immune response to influenza
vaccination in patients with primary immunoglobulin A nephropathy.
An analysis of isotype distribution and size of the influenza-specific
antibodies. Am Soc C/in Invest 84:1070—1075, 1989
5. RoDico JL: Idiopathic IgA nephropathy. Kidney mt 25:717—729, 1984
6. EVANS DJ, WILLIAMS DO, PETERS DK, SlssoNs JGP, BOULTON JONES
JM, OGG CS, CAMERON JS, HOFFBRAND BI: Glomerular depositions
of properdin in Henoch-SchOnlein syndrome and idiopathic focal
nephritis. Br Med J 3:326—328, 1973
7. Roy LP, FIsH AJ, VERNIER RL, MICHAEL AF: Recurrent macroscopic
haematuria, focal nephritis and mesangial depositions of immuno-
globulin and complement. J Pediatr 82:767—772, 1973
8. O'DONOGHUE DJ, DARVILL A, BALLARDIE FW: Mesangial cell au-
toantigens in immunoglobulin A nephropathy and Henoch-Schönlein
purpura. J C/in Invest 88:1522—1530, 1991
9. VAN DEN WALL BAKE AWL, KIRK KA, GAY RE, SWITALSKI LM,
JULIAN BA, JACKSON 5, GAY S, MESTECKY J: Binding of serum
immunoglobulins to collagens in IgA nephropathy and HIV infection.
Kidney Int 42:374—382, 1992
10. FANGER MW, GOLDSTINE SN, SHEN L: Cytofluorographic analysis of
receptors for IgA on human polymorphonuclear cells and monocytes
and the correlation of receptor expression with phagocytosis. Mo!
Immunol 20:2019—2027, 1983
11. MALISZEWSKI CR, SI-lEN L, FANGER MW: The expression of receptors
for IgA on human monocytes and calcitriol-treated HL-60 cells. J
Immunol 135:3878—3881, 1985
12. CHEVALLIER A, MONTEIRO RC, KUBAGAWA H, COOPER MD: Immu-
nofluorescence analysis of IgA binding by human mononuclear cells in
blood and lymphoid tissue. J Immuno! 142:2244—2249, 1989
13. SHEN L, LASSER R, FANGER MW: My43, a monoclonal antibody that
reacts with human myeloid cells inhibits monocyte IgA binding and
triggers function. J Immunol 143:4117—4123, 1989
14. MONTEIRO RC, KUBAGAWA H, COOPER MD: Cellular distribution,
regulation and biochemical nature of an Fccr receptor in humans. J
Exp Med 171:597—613, 1990
15. FANGER MW, PUGH J, BERNIER GM: The specificity of receptors for
IgA on human peripheral polymorphonuclear cells and monocytes.
Ce/I Immunol 60:324—334, 1981
16. ALBRECHTSEN M, YEAMAN OR, KERR MA: Characterization of the
IgA receptor from human polymorphonuclear leucocytes. Immunol
64:201—205, 1988
17. ABU-GHAZALEH RI, FUJISAWA T, MESTECKY J, KYLE RA, GLEICH GJ:
IgA induced eosinophil degranulation. J Immuno! 142:2393—2400,
1989
18. LUM LG, MUCHMORE AV, KEREN D, DECKER J, KosKa I, STROBER W,
BLAESE RM: Fe receptors for IgA on human T lymphocytes. J
Immunol 122:65—69, 1979
19. GUTPA S, PLATSOUCAS CD, Gooo RA: Receptors for IgA on a
subpopulation of human B lymphocytes. Proc Nat! Acad Sci USA
76:4025—4028, 1979
20. FANGER MW, LYDYARD PM: Receptors for IgA on human lympho-
cytes-I. Detection and specificity. Mo! Immunol 18:189—195, 1981
21. WEISBART RH, KACENA A, SCHUH A, GOLDE DW: GM-CSF induces
human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor
activation mechanism. Nature 332:647—648, 1988
22. GORTER A, HIEMSTRA PS, LEIJH PCi, VAN DER SLUYS ME, VAN DEN
BARSELAAR MT, VAN Es LA, DANA MR: IgA and secretory IgA-
opsonized S. aureus induce a respiratory burst and phagocytosis by
polymorphonuclear leucocytes. Immunol 61:303—309, 1987
23. SIBILLE Y, DELACROIX DL, MERILL WW, CHATELAIN B, VAERMAN JP:
IgA-induced chemokinesis of human polymorphonuclear neutrophils:
Requirement of their Fccs receptor. Mol Immuno/ 24:551—559, 1987
24. GORTER A, HIEMSTRA PS, VAN DER VOORT EAM, VAN ES LA, DAI
MR: Binding of human IgAl to rat peritoneal macrophages. Immuno!
64:207—212, 1988
25. GORTER A, HIEMSTRA PS, KLAR-MOHAMAD, VAN Es LA, DANA MR:
Binding, internalization and degradation of soluble aggregates of
human IgA by resident rat peritoneal macrophages. Immunol 64:703—
708, 1988
26. MALISZEWSKI CR, MARCH CJ, SCHOENBORN MA, GIMPEL 5, SHEN L:
Expression cloning of a human Fe receptor for IgA. J Exp Med
172:1665—1672, 1990
27. D0HI K, IWANO M, MURAGUCHI A, HORII Y, HIRAYAMA T, OGAWA 5,
SHIIKI H, HIRANO T, K.ISHIMOTO T, ISI-UKAwA H: The prognostic
significance of urinary interleukin 6 in IgA nephropathy. C/in Ne-
phropathy 35:1—5, 1991
28. VAN DEN DOBBELSTEEN MEA, VAN DER WOUDE FJ, SCHROEIJERS
WEM, VAN Es LA, DANA MR: Soluble aggregates of IgG and
immune complexes enhance the production of IL-6 by renal mesangial
cells. Kidney mt 43:544—553, 1993
29. STRIKER GE, STRIKER LI: Glomerular cell culture. Lab Invest 53:122—
131, 1985
30. RITS M, CORMONT F, BAZIN H, MEYKENS R, VAERMAN JP: Rat
monoclonal antibodies. VI. Production of IgA secreting hybridomas
with specificity for the 2,4-dinitrophenol (DNP) hapten. J Immuno!
Meth 89:81—87, 1986
31. BOGERS WMJM, STAD RK, JANSSEN DJ, PRINS FA, VAN R0OIJEN N,
VAN ES LA, DANA MR: Kupffer cell elimination in viva is associated
with an increased handling of IgA aggregates by liver endothelial cells
in rats. C/in Exp Immunol 85:128—136, 1991
32. Coslo FJ: Human fibronectin is an opsonin for IgG antibody-coated
sheep erythrocytes. J Lab C/in Med 103:613—619, 1984
33. HELLE M, BOEIJE L, AARDEN LA: Functional discrimination between
interleukin 6 and interleukin 1. Eur J Immuno/ 18:1535—1540, 1988
34. SCATCHARD G: The attractions of proteins for small molecules and
ions. Ann P.JYAcad Sci 51:660—672, 1949
35. VEIS JH, YAMASHITA W, LIU YJ, 001 BS: The biology of mesangial
cells in glomerulonephritis. Proc Soc Exp Biol Med 195:160—167, 1990
36. GOMEZ-GUERRERO C, GONZALEZ E, Eoioo J: Evidence for a specific
IgA receptor in rat and human mesangial cells. J Immunol 15 1:7172—
7181, 1993
37. UNDERDOWN BJ, SCHIFF Mi: Immunoglobulin A: Strategic defense
initiative at the mucosal surface. Annu Rev Immunol 4:389—417, 1986
38. BRANDTZAEG P: Mucosal and glandular distribution of immunoglob-
ulin components: Differential localization of free and bound secretory
component in secretory epithelial cells. J Immuno! 112:1553—1559,
1974
39. ASUWELL 0, HARFORD J: Carbohydrate-specific receptors of the liver.
Annu Rev Biochem 51:531—554, 1982
40. KOLB H, VOGT D, HERBERTZ L, CORFIELD A, SCHAUER R, SCHLEP-
PER-SCHAFER J: The galactose-specific lectins on rat hepatocytes and
Kupifer cells have identical binding characteristics. Hoppe-Sey!er's Z
Physiol Chem 361:1747—1750, 1980
41. STOCKERT Ri, KRESSNER MS, COLLINS JC, STERNLIEB I, MORELL AG:
I8A interaction with the asialoglycoprotein receptor. Proc Nati Acad
Sci USA 79:6229—6231, 1982
42. FARGEAS CA, SCHOLLER M, PINI A, WACHSMANN D, POINDRON P,
K1.EIN JP: Purification and characterization of rat macrophage Fe
van den Dobbeisteen et al: IgA enhances the release of IL-6 by MC 519
receptor and binding factor for IgA. Biochem Biophys Acta 1037:344—
350, 1990
43. WEISS MA, 001 BS, ENGVALL E, RUOSLAHTI E: Immunofluorescent
localization of fibronectin in the human kidney. Lab Invest 41:340—
347, 1979
44. CEDERHOLM B, WIESLANDER J, BYGREN P, HEINEGARD D: Circulating
complexes containing IgA and fibronectin in patients with primary
IgA nephropathy. Proc Nati Acad Sci USA 85:4865—4868, 1988
45. SUEMATSU S, MATSUDA M, AOZASA K, Aiii S, NAKANO N, OHNO S,
MIYAZAKI J, YAMAMURA K, HIRANO T, KISHIMOTO T: IgGl plasma-
cytosis in interleukin-6 transgenic mice. Proc Nati Acad Sci USA
86:7547—7551, 1989
